YOLFTbeta
SynBiotic SE

SynBiotic SE

SBX · XETRA · Healthcare / Drug Manufacturers - Specialty & Generic

0.124EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.124
Open0.11
Day Range0.11 – 0.124
52-Week Range0.495 – 3.85
Volume344
Market Cap6.18M
P/E (TTM)0.00
Forward P/E303.03
EPS-1.66
Dividend Yield0.00%
Beta0.63
50-Day Avg0.9168
200-Day Avg1.71

About

SynBiotic SE, together with its subsidiaries, engages in the pharmaceutical business in Germany and Europe. It is involved in the cultivation, research, development, production, and distribution of medicinal cannabis; industrial hemp; and cannabidiol and cannabinoid-based products. The company was incorporated in 2024 and is based in Düsseldorf, Germany.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Daniel Kruse
  • Employees79
  • HeadquartersMünsterstraße 336, Düsseldorf, Germany, 40470, Germany
  • Websitehttps://www.synbiotic.com

Leadership

  • Mr. Daniel KruseMD & Director
  • Ms. Rebecca Kruse-Rosetti?Head of Finance

Financials

Income Statement

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Revenue005.45M8.65M8.17M3.86M14.31M
Growth (%)---+58.81%-5.58%-52.71%+270.47%
Cost of Revenue--1.73M3.86M4.59M2.35M9.44M
Gross Profit--3.71M4.79M3.57M1.51M4.86M
Gross Margin--68.17%55.33%43.75%39.01%33.98%
Operating Expense--4.43M16.22M28.47M12.50M15.40M
Operating Income-822-13.43K-720.71K-11.44M-24.90M-11.00M-10.54M
Operating Margin---13.23%-132.23%-304.88%-284.82%-73.66%
EBITDA-822-13.43K-716.12K-5.00M-7.49M-7.12M-2.03M
EBITDA Margin---13.15%-57.78%-91.67%-184.46%-14.16%
Net Income-822-13.43K-880.39K-12.72M-24.36M-10.63M-9.72M
Net Income Margin---16.17%-147.13%-298.35%-275.31%-67.92%
Interest Expense0022.87K46.64K188.90K195.24K428.72K
Interest Expense % of Total Revenue--0.42%0.54%2.31%5.06%3.00%

Balance Sheet

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Assets249.68K238.25K35.03M60.65M40.62M34.92M45.71M
Total Liabilities-2.50K9.53M23.92M17.83M19.59M24.70M
Total Equity249.18K235.75K25.49M35.00M22.59M15.79M22.87M
Cash-13.25K5.99M3.20M966.56K89.21K543.17K
Total Debt--366.88K3.43M4.45M3.68M5.51M
Net Debt--13.25K-5.62M232.72K3.49M3.59M4.97M

Cash Flow

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-11.43K-11.43-1.26M-5.14M-7.00M-2.92M-503.13K
Investing Cash Flow-1.13M-1.13M-1.13M-3.06M-68.16K-732.79K-2.06M
Financing Cash Flow8.25M8.37M8.37M5.42M4.83M2.78M2.84M
Capital Expenditure17.85K17.85K2.14M365.61K478.15K19.18K222.94K
Free Cash Flow--11.43-3.40M-5.51M-7.47M-2.94M-726.07K
FCF to OCF-100.00%269.17%107.11%106.84%100.66%144.31%

Earnings

Report DateSep 30, 2020Jun 30, 2021Sep 28, 2021Aug 16, 2024
EPS Estimate0.000.000.000.00
EPS Actual-0.04-0.95-0.130.00
Surprise----
Timing----

Key Statistics & Ratios

Market Cap6.18M
Enterprise Value9.29M
Trailing P/E0.00
Forward P/E303.03
Price / Sales0.42
Price / Book0.18
EPS-1.66
Book Value3.35
Revenue (TTM)14.86M
Gross Profit (TTM)5.41M
EBITDA-2.51M
Profit Margin-65.39%
Operating Margin-29.81%
Return on Equity-59.95%
Return on Assets-5.07%
Shares Outstanding7.27M
Shares Float0
Beta0.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%